Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AHB-171 Injection in Chronic Hepatitis B
ChiCTR2600128219Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AHB-171 in Chronic Hepatitis B (CHB) (5 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Efficacy evaluation endpoint indicators. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
AHB-171
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600128219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128219.